Sarepta Therapeutics (SRPT +1.9%) may be up 100% YTD, but that doesn't mean it can't rally another 294% or so, Deutsche's Robyn Karnauskas thinks.
Karnauskas — whose price target is currently $71 — further highlights the apparent efficacy disparity between drisapersen and eteplirsen noting that patients taking eteplirsen saw "stabilization in 6MWD as early as 24 weeks [and remained] stable even at 96 weeks."
Here's the real kicker though: "We could see FV in $98-$125 range if we assume 100% probability to Eteplirsen and 80-100% market share in treated patients. If we assume 100% probability to their other exon program, we get to SRPT FV of $213/share." (emphasis added)